News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Xeris Pharmaceuticals Receives U.S. Patent For Its Novel, Stable Non-Aqueous Glucagon Formulations



4/16/2014 9:19:55 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Austin, Texas, April 16, 2014 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris") announces today that is has been granted U.S. Patent No. 8,697,644, "Stable Formulations for Parenteral Injection of Peptide Drugs". The new formulation technology will enable peptides that are typically given as aqueous injections to be reformulated into biocompatible, concentrated, non-aqueous solutions. Different from their predecessors, these formulations can be directly injected without reconstitution, saving time during medical emergencies related to Type 1 diabetes among other diseases. This is the second patent issued that supports Xeris' novel,non-aqueous drug delivery technology.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES